Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
The final analysis of overall survival (OS) in GOG-0218, (a phase III, randomized trial of bevacizumab in women with newly diagnosed stage III/IV ovarian, cancer), shows no OS benefit for patients who received bevacizumab with chemo compared with chemotherapy alone.
This result confirms previous evidence, which demonstrated improvement in progression-free survival (PFS) without OS increase. The OS at 8.5 years was 20% with no significant difference between the two patient groups.
Bevacizumab has known toxicity with hypertension, proteinuria and neutropenia being indications to discontinue treatment. The high cost is financially toxic.
In 2011, the US Food and Drug Administration (FDA) revoked accelerated approval of bevacizumab for metastatic breast cancer (partly because of a lack of OS benefit). This result will cause reappraisal of the current FDA approval for maintenance and initial therapy for advanced ovarian cancer.
Monoclonal antibody therapy
No comments:
Post a Comment